RaneeMehraMD

Oncology • Baltimore, MD

Head & Neck Cancer, Thoracic Cancer

Professor of Medicine

Join to view full profile

Dr. Mehra is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mehra's full profile

Already have an account?

Office
22 S. Greene St.
Baltimore, MD 21201

Summary

Solid Tumor Section Head, Director of Head and Neck Oncology

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
NYU Grossman School of MedicineResidency, Internal Medicine, 1999 - 2002
New York University School of MedicineClass of 1999

Certifications & Licensure

MD State Medical License 2016 - 2025
DC State Medical License 2017 - 2018
PA State Medical License 2006 - 2016
CT State Medical License 2002 - 2006
NY State Medical License 2001 - 2003

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer Start of enrollment: 2006 Oct 01
Terminated
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Start of enrollment: 2009 Dec 16
Completed
Phase 1
Biomakers in Tissue Samples From Patients With Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck Previously Treated With Cisplatin With or Without Cetuximab Start of enrollment: 2010 Aug 05
Completed
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer Start of enrollment: 2011 Feb 16
Completed
Phase 2
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer Start of enrollment: 2013 Jun 01
Completed
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Start of enrollment: 2019 Jan 10
Active, not recruiting
Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors Start of enrollment: 2019 May 07
Recruiting
Phase 2
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors Start of enrollment: 2019 Oct 09
Terminated
Phase 2
1922GCCC: Pembro and Bavituximab for Squamous Cell Carcinoma of Head and Neck Start of enrollment: 2020 Jan 13
Active, not recruiting
Phase 2
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Start of enrollment: 2020 Oct 13
Active, not recruiting
Phase 2
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer Start of enrollment: 2021 May 07
Recruiting
Phase 2
A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors Start of enrollment: 2020 Jul 22
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy Start of enrollment: 2022 Sep 30
Recruiting
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

230 citations
Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy
Rajani Ravi, Kimberly A. Noonan, Vui Pham, Rishi Bedi, Alex Zhavoronkov
Nature Communications. 2018-02-21
969 citations
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, p...
Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau, José Dinis, Lisa Licitra
Lancet. 2019-01-12
5 citations
Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation.
Alessandro Russo, Katherine A Scilla, Ranee Mehra, Allison Gittens, Michael G McCusker
Clinical Lung Cancer. 2023-11-01

Journal Articles

Pattern of Planned Systemic Therapy Usage in Newly Diagnosed, Nonmetastatic Squamous Cell Carcinoma of the Head and Neck in a Commercially Insured Population in the Un...
Christine G Gourin, Ranee Mehra, Hyunseok Kang, Arlene A Forastiere, Ana P Kiess, Head & Neck

Press Mentions

Head and Neck Cancer Awareness Month: 2020 Immunotherapy Research UpdateApril 14th, 2020
Peregrine Pharmaceuticals Announces First Patient Dosed in Phase II Clinical Trial Evaluating Bavituximab Treatment Combination in Patients with Newly Diagnosed GlioblastomaSeptember 7th, 2017
Pembrolizumab and Cetuximab-Treated Head and Neck Cancer: Activity Confirmed but No SurprisesJuly 25th, 2017
Join now to see all